Delirium in Home-dwelling Old People Receiving Home Nursing Care

August 21, 2018 updated by: Maria Krogseth, Oslo University Hospital
Study the prevalence of delirium among old persons with home-nursing care living in the community. By recruiting the persons in a stable phase, the investigators wish to study the influence of an episode of delirium upon further cognitive and physical function.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

211

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Sandefjord, Norway
        • Sandefjord kommune

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Persons older than 65 years living in their own home receiving home nursing care at least once a week.

Description

Inclusion Criteria:

  • Home nursing service at least once a week.
  • Home dwelling (not permanently institutionalised)
  • Age 65 years or more
  • Informed consent by the patient or a close relative (if the patient is unable to give a valid informed consent)

Exclusion Criteria:

  • Patient or relative denies inclusion
  • Terminal illness
  • Patients diagnosed with dementia with Lewy bodies (its fluctuating course makes the diagnosis of delirium challenging)
  • Patients with chronic diseases that have needed assistance from the home nursing service before the age of 65.
  • Assistance from the home nursing service is due to addictive substances.
  • Assistance from the home nursing service is due to psychiatric illnesses other than dementia.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Trajectory of cognitive function using the MoCa test
Time Frame: 2 years
The impact of an episode of delirium upon cognitive function measured by the Montreal Cognitive Assessment every 6th months for two years.
2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Torgeir Bruun Wyller, MD, PhD, Oslo University Hospital, University of Oslo

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 11, 2015

Primary Completion (Actual)

July 8, 2018

Study Completion (Actual)

July 8, 2018

Study Registration Dates

First Submitted

February 20, 2017

First Submitted That Met QC Criteria

February 22, 2017

First Posted (Actual)

February 28, 2017

Study Record Updates

Last Update Posted (Actual)

August 22, 2018

Last Update Submitted That Met QC Criteria

August 21, 2018

Last Verified

August 1, 2018

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Delirium

3
Subscribe